Case report: Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient

Report describes use of omalizumab in a 70-yr-old male with bullous pemphigoid unresponsive to topical and systemic immunosuppressive treatment. After 3 months, there was an absence of blisters with no adverse effects and after 6 months omlaizumab was stopped with no relapse.


European Journal of Hospital Pharmacy